HCPCS code J1826 – Injection, interferon beta-1a

Key takeaways

HCPCS code J1826 describes injection, interferon beta-1a, 30 mcg, billed once per Avonex administration.

Medicare Part B pays J1826 at ASP plus 6%, and only when a provider administers the drug.

Every claim needs a supporting ICD-10 code such as G35, the NDC, and the correct place of service.

Place of service changes what Medicare pays for the injection code, not the allowed amount for the drug.

Pabau carries the documented code, NDC, and diagnosis onto the claim, so fewer J1826 lines come back.

HCPCS code J1826: definition and key attributes

HCPCS code J1826 is a Level II alphanumeric code maintained by the Centers for Medicare and Medicaid Services (CMS). Its official descriptor is: Injection, interferon beta-1a, 30 mcg. One unit equals one 30 mcg injection. Avonex, manufactured by Biogen, is the primary product billed under this code.

One common source of claim rejections is billing more than one unit when the patient receives a single 30 mcg dose. Avonex is dosed at 30 mcg once weekly by intramuscular injection. Bill one unit of J1826 per administration event.

Medicare coverage and eligibility for HCPCS code J1826

Medicare Part B covers J1826 when the drug is administered by or incident to a physician in an outpatient or office setting. CMS Article A52571 lists interferon beta-1a on the self-administered drug exclusion list. Medicare will not cover J1826 when the patient self-administers at home.

Coverage applies only when the provider gives the injection during the encounter. Claims filed without documentation of provider administration are the leading cause of J1826 denials on Medicare.

• Eligible setting: Provider office (POS 11), outpatient hospital (POS 22), or another outpatient setting where the practice buys and administers the drug
• Not covered: Patient self-administration at home, and drugs dispensed by a retail pharmacy for home use
• Medical necessity: Each claim needs an ICD-10-CM diagnosis supporting interferon beta-1a for a relapsing form of multiple sclerosis
• Incident-to rules: When non-physician staff give the injection, the physician must be present in the suite and the service must belong to the care plan

J1826 Medicare reimbursement and fee schedule

CMS reimburses J1826 at the Average Sales Price (ASP) plus 6%. That methodology is the standard Part B drug reimbursement formula, and CMS updates ASP pricing quarterly. The allowed amount therefore changes four times a year. Do not hardcode a dollar figure in your billing system without confirming the current quarter’s rate from the CMS ASP drug pricing files.

National Drug Code (NDC) for J1826 and Avonex

Many payers, including Medicare, require the NDC number on the claim alongside J1826. The NDC identifies the exact drug product: manufacturer, product, and package size. Avonex 30 mcg/0.5 mL prefilled syringe carries NDC 59627-0013-03 (Biogen). Packaging changes can change that number, so verify it against the AAPC HCPCS code lookup or the FDA NDC directory before submission.

The claim form is the CMS-1500, or the 837P electronic equivalent. Report qualifier N4, then the 11-digit NDC, then the quantity and unit of measure. A missing NDC produces a rejection rather than a denial, which means the claim comes back unprocessed instead of adjudicated.

ICD-10 diagnosis codes used with HCPCS code J1826

Every J1826 claim needs at least one ICD-10-CM diagnosis code that establishes medical necessity for interferon beta-1a therapy. The primary indication is multiple sclerosis, particularly relapsing forms. Confirm each code is active in the current ICD-10-CM year before filing.

G35 is the code most MS practices bill with J1826. Some commercial payers ask for more specificity. Check the local coverage determination (LCD) and your payer contract before filing G36.9 or G37.9 as the primary diagnosis. If you need to confirm a descriptor first, the ICD-10 codes for billers hub lists each one in full.

Required modifiers for J1826 claims

Modifier selection for HCPCS code J1826 depends on the route of administration and the claim context. Using the wrong modifier, or omitting one that the payer requires, is a common reason J1826 claims are denied rather than paid.

For standard Avonex intramuscular administration at POS 11, most practices submit J1826 without a route-of-administration modifier unless the payer asks for one. Confirm modifier requirements with your Medicare Administrative Contractor (MAC) before your first J1826 claim.

Place of service codes on a J1826 claim

The place of service (POS) code records where the injection was given. It does not change what Medicare allows for the drug, because Part B pays J1826 at ASP plus 6% in every setting. What the POS code does change is the payment for the administration code billed with it, since CPT 96372 carries separate facility and non-facility rates.

Report the POS that matches where the encounter happened, rather than choosing one to influence payment. An inaccurate POS is a compliance problem, and it will not lift the drug’s allowed amount.

Buy-and-bill process for HCPCS code J1826

Avonex is typically acquired through the buy-and-bill model. The practice purchases the drug, administers it during the encounter, and bills for both the drug (J1826) and the administration code. The practice carries the acquisition cost until reimbursement arrives, so a rejected line ties up money it has already spent. Denial management is what gets that money back on Part B drug claims.

1. Drug acquisition: Purchase Avonex 30 mcg prefilled syringes through an authorized distributor. Record the acquisition cost, lot number, and NDC from the invoice.
2. Patient eligibility check: Verify Medicare Part B coverage and confirm no secondary payer policy coordinates first.
3. Administration: Give the intramuscular injection. Document the time, site, dose, lot number, and the administering provider’s credentials.
4. Claim preparation: Pair J1826 with the injection administration code, typically 96372. Attach the NDC in the required format, the ICD-10-CM diagnosis, the POS code, and any required modifier.
5. Submission and follow-up: Submit the 837P claim or CMS-1500 form and monitor the remittance for the J1826 line. If it is denied, read the CARC and RARC codes to see whether documentation, a modifier, or coverage caused it.

Step four is where most J1826 lines fail, because six separate fields have to agree before the claim will adjudicate.

Documentation requirements to support J1826 claims

Incomplete documentation is the second most common reason J1826 claims are denied after adjudication. Medicare and most commercial payers expect a full documentation trail before approving a high-cost Part B drug. Build the checks into the encounter itself, so the record is complete before the charge leaves the office.

• Physician order or prescription: A signed order specifying interferon beta-1a 30 mcg IM, with frequency and duration
• Diagnosis documentation: Chart notes confirming the MS diagnosis, the relapsing course, and the rationale for interferon therapy
• Administration record: Date, time, site, lot number, NDC, dose given, and the name of the administering provider
• Medical necessity justification: Documentation that the patient meets coverage criteria, including prior treatment history where applicable
• Prior authorization (if required): The PA approval number, since commercial payers often require authorization for Avonex even when Medicare does not
• Drug acquisition record: An invoice or purchase order confirming the practice bought the drug for in-office administration

Related and adjacent HCPCS codes

Coders working on MS drug billing will meet several codes adjacent to J1826. Knowing the distinctions prevents misbilling when a patient switches disease-modifying therapy (DMT). Two of the neighboring J-codes are not interferons at all, despite sitting a few digits away.

How Pabau supports J1826 claim accuracy

A high-cost injectable claim carries more moving parts than a standard office visit. The code, the units, the NDC, the diagnosis, the place of service, and any required modifier all have to match what the record says happened. Practices that manage this by hand depend on the biller catching every field, every time.

Pabau is practice management software that keeps the clinical record and the billing record in one system. When an Avonex administration is charted, the biller works from that entry instead of re-keying it from a printout. Our claims software for practices then submits the line and tracks its status through to the remittance.

The outcome is a shorter path between administration and payment on a drug the practice has already bought. Fewer lines come back for a missing NDC or a diagnosis that never made it onto the claim.

Keep buy-and-bill claims in step with the record

Pabau links each drug administration record to the claim it belongs on, then tracks that claim through to the remittance. Your billers confirm fields rather than re-key them.

Book a demo

Conclusion

J1826 is simple in its descriptor and demanding in its claim requirements. A verified NDC, an active companion diagnosis, an accurate place of service, and proof of provider administration all have to be present. Add whatever modifier the payer asks for, and the line adjudicates cleanly.

Practices paid on the first pass build those checks into the administration itself, rather than into claims review a week later. That is a workflow decision more than a coding one, and it is the one worth making before the next Avonex order arrives.

Book a demo to see how Pabau keeps the drug record and the claim in step for specialty injectables.

Continue your research

Need to understand the full lifecycle of a Part B drug claim? Medical billing fundamentals walks through how provider claims move from service to payment.

Want to reduce claim denials across your injectable drug portfolio? Denial management in healthcare explains how to build a structured appeals and prevention workflow.

Looking for the compliance requirements behind high-cost drug billing? Medical billing compliance covers the documentation and audit standards that apply to Part B injectables.

Not sure what makes a claim pass on the first submission? What is a clean claim sets out the fields payers check before a line is adjudicated.

Building the charge document behind the claim? Superbill explains which codes and patient details belong on it before billing.

Frequently asked questions